
	For the Three Months Ended September 30, 2024
	Medical Office and Life Science Portfolio		SHOP		Non-Segment		Consolidated
Revenues:
Rental income	$	52,901	$	—	$	8,734	$	61,635
Residents fees and services	—		312,005		—		312,005
Total revenues	52,901		312,005		8,734		373,640

Expenses:
Property operating expenses	25,074		284,572		51		309,697
Depreciation and amortization	18,773		47,343		2,843		68,959
General and administrative	—		—		13,933		13,933
Acquisition and certain other transaction related costs	—		—		331		331
Impairment of assets	23,031		—		—		23,031
Total expenses	66,878		331,915		17,158		415,951

Gain on sale of properties	111		—		—		111

Interest and other income	—		—		2,575		2,575
Interest expense	(2,319)		(54)		(57,070)		(59,443)

Loss before income tax expense and equity in net earnings (losses) of investees	(16,185)		(19,964)		(62,919)		(99,068)
Income tax expense	—		—		(148)		(148)
Equity in net earnings (losses) of investees	1,707		—		(1,180)		527


Net loss	$	(14,478)	$	(19,964)	$	(64,247)	$	(98,689)


	For the Nine Months Ended September 30, 2024
	Medical Office and Life Science Portfolio		SHOP		Non-Segment		Consolidated
Revenues:
Rental income	$	161,605	$	—	$	25,550	$	187,155
Residents fees and services	—		928,653		—		928,653
Total revenues	161,605		928,653		25,550		1,115,808

Expenses:
Property operating expenses	73,253		847,526		587		921,366
Depreciation and amortization	58,488		141,176		7,785		207,449
General and administrative	—		—		27,763		27,763
Acquisition and certain other transaction related costs	—		—		2,243		2,243
Impairment of assets	41,718		—		—		41,718
Total expenses	173,459		988,702		38,378		1,200,539

Loss on sale of properties	(18,976)		—		—		(18,976)

Interest and other income	—		—		7,215		7,215
Interest expense	(3,435)		(183)		(172,103)		(175,721)
Loss on modification or early extinguishment of debt	—		—		(209)		(209)
Loss before income tax expense and equity in net (losses) earnings of investees	(34,265)		(60,232)		(177,925)		(272,422)
Income tax expense	—		—		(505)		(505)
Equity in net (losses) earnings of investees	(18,173)		—		8,291		(9,882)


Net loss	$	(52,438)	$	(60,232)	$	(170,139)	$	(282,809)


	For the Three Months Ended September 30, 2023
	Medical Office and Life Science Portfolio		SHOP		Non-Segment		Consolidated
Revenues:
Rental income	$	55,058	$	—	$	8,332	$	63,390
Residents fees and services	—		293,134		—		293,134
Total revenues	55,058		293,134		8,332		356,524

Expenses:
Property operating expenses	25,784		272,445		203		298,432
Depreciation and amortization	20,175		44,587		2,474		67,236
General and administrative	—		—		6,954		6,954
Acquisition and certain other transaction related costs	—		—		3,676		3,676
Impairment of assets	427		729		—		1,156
Total expenses	46,386		317,761		13,307		377,454



Interest and other income	—		115		3,128		3,243
Interest expense	(119)		(79)		(47,560)		(47,758)


Income (loss) before income tax expense and equity in net losses of investees	8,553		(24,591)		(49,407)		(65,445)
Income tax expense	—		—		(189)		(189)
Equity in net losses of investees	(145)		—		—		(145)


Net income (loss)	$	8,408	$	(24,591)	$	(49,596)	$	(65,779)


	For the Nine Months Ended September 30, 2023
	Medical Office and Life Science Portfolio		SHOP		Non-Segment		Consolidated
Revenues:
Rental income	$	165,448	$	—	$	25,753	$	191,201
Residents fees and services	—		857,572		—		857,572
Total revenues	165,448		857,572		25,753		1,048,773

Expenses:
Property operating expenses	73,237		796,733		770		870,740
Depreciation and amortization	63,065		129,891		7,474		200,430
General and administrative	—		—		20,111		20,111
Acquisition and certain other transaction related costs	—		—		9,812		9,812
Impairment of assets	14,034		4,346		—		18,380
Total expenses	150,336		930,970		38,167		1,119,473

Gain on sale of properties	—		1,233		—		1,233
Gains on equity securities, net	—		—		8,126		8,126
Interest and other income	—		1,581		10,991		12,572
Interest expense	(344)		(502)		(142,076)		(142,922)

Loss on modification or early extinguishment of debt	—		—		(1,075)		(1,075)
Income (loss) before income tax expense and equity in net earnings of investees	14,768		(71,086)		(136,448)		(192,766)
Income tax expense	—		—		(379)		(379)
Equity in net earnings of investees	2,137		—		—		2,137
Net income (loss)	$	16,905	$	(71,086)	$	(136,827)	$	(191,008)